Trials / Completed
CompletedNCT00233909
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
An Open-Label, Phase I/II Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- Sponsor
- Kanisa Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar may help Gemtuzumab Ozogamicin (GO) kill more cancer cells by making cancer cells more sensitive to the drug. It is not known whether Gemtuzumab Ozogamicin (GO) is more effective with or without zosuquidar in treating acute myeloid leukemia.
Detailed description
Purpose: Phase I: Determine the optimal dose and schedule of GO and zosuquidar when used in combination. Phase II: Determine the complete remission rate (CR+CRp)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zosuquidar | |
| DRUG | gemtuzumab ozogamicin |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2005-10-06
- Last updated
- 2008-04-01
Source: ClinicalTrials.gov record NCT00233909. Inclusion in this directory is not an endorsement.